ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma

Wang, Peipei; Chen, Yueyun; Long, Qingqin; Li, Qing; Tian, Jiangfang; Liu, Ting; Wu, Yong*; Ding, Zhenyu*四川大学; y
Journal for ImmunoTherapy of Cancer2021-10DOI: 10.1136/jitc-2021-002836
33被引16阅读
引用收藏
分享

摘要

Background Immune checkpoint (IC) blockades (ICBs) significantly improve patients' clinical outcomes with solid tumors. Because the objective response rate of single-agent ICB is limited, it is meaningful to explore the combination of ICs for immunotherapy. Methods RNA sequencing data of 95 newly diagnosed patients with esophageal squamous cell carcinoma (ESCC) from The Cancer Genome Atlas (TCGA) database were used to explore the prognostic significance of ICs. The results were validated by immunohistochemistry of 58 ESCC tissue samples from our clinical center. Results The results of both TCGA and validation data suggested that high expression of programmed cell death 1 ligand 1 (PD-L1), T-cell immunoglobulin and mucin-domain-containing-3 (TIM3), and T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) was associated with poor overall survival (OS) of patients with ESCC. Importantly, PD-L1/TIM3 or PD-L1/TIGIT was the optimal combination for predicting poor OS and short restricted mean survival time of patients with ESCC and was an independent prognostic factor. Moreover, a nomogram model constructed by PD-L1, TIM3, and TIGIT together with the primary tumor, regional lymph node, distant metastasis stage could provide a concise and precise prediction of 1-year and 2-year OS rates and median survival time. PD-L1/TIM3 or PD-L1/TIGIT had a positive correlation with CD8+ T cells. Notably, PD-1 and TIM3/TIGIT were primarily coexpressed on CD8+ tumor-infiltrating lymphocyte in patients with ESCC by multiplexed immunofluorescence. Conclusion High expression of ICs was associated with poor OS of patients with ESCC. PD-L1/TIM3 and PD-L1/TIGIT were the optimal combinations for predicting OS, which might be potential targets for future ICBs therapy of ESCC.

学科与关键词

关键词
costimulatory and inhibitory T-cell receptorsimmunityimmunohistochemistrytumor biomarkers
相关
加载中…
  • Analysis of multiple programmed cell death-related prognostic genes and functional validations of necroptosis-associated genes in oesophageal squamous cell carcinoma
    Cao, Kui; Zhu, Jinhong; Lu, Mengdi; Zhang, Jinfeng; Yang, Yingnan; Ling, Xiaodong; Zhang, Luquan; Qi, Cuicui; Wei, Shenshui; Zhang, Yanqiao*; Ma, Jianqun*EBioMedicine, 2024, 99: 104920.
  • Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma
    Zhang, Zhengfeng; Yang, Lei; Wang, Dazhen; Ruan, Yuli; Zhang, Jianji; Zhao, Lu; Yang, Liu; Lou, Changjie*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231169981.被引 2
  • Immune Checkpoint Gene Expression Profiling Identifies Programmed Cell Death Ligand-1 Centered Immunologic Subtypes of Oral and Squamous Cell Carcinoma With Favorable Survival
    Yu, Yang*; Tang, Huiwen; Franceschi, Debora; Mujagond, Prabhakar; Acharya, Aneesha; Deng, Yupei; Lethaus, Bernd; Savkovic, Vuk; Zimmerer, Ruediger; Ziebolz, Dirk; Li, Simin; Schmalz, GerhardFrontiers in Medicine, 2022, 8: 759605.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal for ImmunoTherapy of Cancer
发表日期
2021-10
卷期
第 9 卷, 第 10 期
页码
e002836
DOI
10.1136/jitc-2021-002836
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
Clinical Research Incubation Project, West China Hospital, Sichuan University [2020HXFH056]; National Natural Science Foundation of China [31971164]

作者

  • W

    Wang, Peipei (第一作者)

    sichuan univ

  • C

    Chen, Yueyun

    sichuan univ

查看全部 8 位作者收起作者
  • L

    Long, Qingqin

    2

  • L

    Li, Qing

    sichuan univ

  • T

    Tian, Jiangfang

    sichuan univ

  • L

    Liu, Ting

    sichuan univ

  • W

    Wu, Yong (通讯)

    2

  • D

    Ding, Zhenyu (通讯)

    sichuan univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417